Added to YB: 2026-02-04
Pitch date: 2026-02-02
GOSS [neutral]
Gossamer Bio, Inc.
-95.52%
current return
Author Info
No bio for this author
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Market Cap
$65.6M
Pitch Price
$198.40
Price Target
8.67 (-2%)
Dividend
N/A
EV/EBITDA
-0.31
P/E
-0.21
EV/Sales
0.91
Sector
Biotechnology
Category
special_situation
Gossamer Bio, Inc. - $GOSS
GOSS: Biotech binary on seralutinib PAH inhaled therapy w/ PROSERA Phase 3 data Feb 2026. 390 patients, 6-min walk primary endpoint. CEO Hasnain sold Receptos for $7.2B. Chiesi partnership. Analysts: $8.67 avg PT vs $2.28 (280% upside). Risk: Phase 2 mixed efficacy. $180M cash runway.
Read full article (1 min)